Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure

被引:55
作者
Eliopoulos, Nicoletta
Gagnon, Raymonde F.
Francois, Moira
Galipeau, Jacques
机构
[1] McGill Univ, Ctr Hlth, Lady Davis Inst Med Res, Montreal, PQ, Canada
[2] McGill Univ, Ctr Hlth, Div Nephrol, Montreal, PQ, Canada
[3] McGill Univ, Jewish Gen Hosp, Div Hematol Oncol, Montreal, PQ H3T 1E2, Canada
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 17卷 / 06期
关键词
D O I
10.1681/ASN.2005101035
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The goal of this research was to develop a strategy to couple stem cell and gene therapy for in vivo delivery of erythropoietin (Epo) for treatment of anemia of ESRD. It was shown previously that autologous bone marrow stromal cells (MSCs) can be genetically engineered to secrete pharmacologic amounts of Epo in normal mice. Therefore, whether anemia in mice with mild to moderate chronic renal failure (CRF) can be improved with Epo gene-modified MSCs (Epo(+)MSCs) within a subcutaneous implant was examined. A cohort of C57BL/6 mice were rendered anemic by right kidney electrocoagulation and left nephrectomy. In these CRF mice, the hematocrit (Hct) dropped from a prenephrectomy baseline of approximately 55% to 40% after induction of renal failure. MSCs from C57BL/6 donor mice were genetically engineered to secrete murine Epo at a rate of 3 to 4 units of Epo/10(6) cells per 24 h, embedded in a collagen-based matrix, and implanted subcutaneously in anemic CRF mice. It was observed that Hct increased after administration of Epo(+)MSCs, according to cell dose. Implants of 3 million Epo(+)MSCs per mouse had no effect on Hct, whereas 10 million led to a supraphysiologic effect. The Hct of CRF mice that received 4.5 or 7.5 million Epo(+)MSCs rose to a peak 54 +/- 4.0 or 63 +/- 5.5%, respectively, at 3 wk after implantation and remained above 48 or 54% for > 19 wk. Moreover, mice that had CRF and received Epo(+)MSCs showed significantly greater swimming exercise capacity. In conclusion, these results demonstrate that subcutaneous implantation of Epo-secreting genetically engineered MSCs can correct anemia that occurs in a murine model of CRE
引用
收藏
页码:1576 / 1584
页数:9
相关论文
共 68 条
  • [1] Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy
    Binley, K
    Askham, Z
    Iqball, S
    Spearman, H
    Martin, L
    de Alwis, M
    Thrasher, AJ
    Ali, RR
    Maxwell, PH
    Kingsman, S
    Naylor, S
    [J]. BLOOD, 2002, 100 (07) : 2406 - 2413
  • [2] Subtherapeutic erythropoietin and insulin-like growth factor-1 correct the anemia of chronic renal failure in the mouse
    Brox, AG
    Zhang, F
    Guyda, H
    Gagnon, RF
    [J]. KIDNEY INTERNATIONAL, 1996, 50 (03) : 937 - 943
  • [3] Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling
    Calvillo, L
    Latini, R
    Kajstura, J
    Leri, A
    Anversa, P
    Ghezzi, P
    Salio, M
    Cerami, A
    Brines, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) : 4802 - 4806
  • [4] Mesenchymal stem cells: building blocks for molecular medicine in the 21st century
    Caplan, AI
    Bruder, SP
    [J]. TRENDS IN MOLECULAR MEDICINE, 2001, 7 (06) : 259 - 264
  • [5] Biology of bone marrow stroma
    Clark, BR
    Keating, A
    [J]. BONE MARROW TRANSPLANTATION: FOUNDATIONS FOR THE 21ST CENTURY, 1995, 770 : 70 - 78
  • [6] Science review: Recombinant human erythropoietin in critical illness: a role beyond anemia?
    Coleman, T
    Brines, M
    [J]. CRITICAL CARE, 2004, 8 (05): : 337 - 341
  • [7] Age-dependent modifications of gene expression in human fibroblasts
    Cristofalo, VJ
    Volker, C
    Francis, MK
    Tresini, M
    [J]. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1998, 8 (01): : 43 - 80
  • [8] Mesenchymal stem cells: Biology and potential clinical uses
    Deans, RJ
    Moseley, AB
    [J]. EXPERIMENTAL HEMATOLOGY, 2000, 28 (08) : 875 - 884
  • [9] Ebert BL, 1999, BLOOD, V94, P1864
  • [10] Correction of anemia in uremic mice by genetically modified peritoneal mesothelial cells
    Einbinder, T
    Sufaro, Y
    Yusim, I
    Byk, G
    Passlick-Deetjen, J
    Chaimovitz, C
    Douvdevani, A
    [J]. KIDNEY INTERNATIONAL, 2003, 63 (06) : 2103 - 2112